




(86) Date de dépôt PCT/PCT Filing Date: 2011/10/06
(87) Date publication PCT/PCT Publication Date: 2012/04/19
(85) Entrée phase nationale/National Entry: 2013/03/18
(86) N° demande PCT/PCT Application No.: RU 2011/000785
(87) N° publication PCT/PCT Publication No.: 2012/050483
(30) Priorité/Priority: 2010/10/11 (RU2010141697)

(51) Cl.Int./Int.Cl. *C08B 15/00* (2006.01),
A61K 31/717 (2006.01), *A61P 25/28* (2006.01)
(71) Demandeur/Applicant:
OBSHESTVO S OGRANICHENNOI
OTVETSTVENNOSTYU "NIARMEDIK PLUS", RU
(72) Inventeurs/Inventors:
ERSHOV, FELIX IVANOVICH, RU;
NESTERENKO, VLADIMIR GEORGIEVICH, RU;
SARYMSAKOV, ABDUSHUKUR ABDUKHALILOVICH,
UZ;
ALEKSEEVA, NATALYA URYEVNA, RU
(74) Agent: NORTON ROSE FULLBRIGHT CANADA
S.E.N.C.R.L., S.R.L.

(54) Titre : PROCEDE DE PRODUCTION ET D'UTILISATION D'UN COPOLYMERE DE CARBOXYMETHYLCELLULOSE
DE SODIUM ET DE GOSSYPOL
(54) Title: METHOD FOR PRODUCING AND USING A COPOLYMER OF SODIUM CARBOXYMETHYL CELLULOSE
AND GOSSYPOL



(57) **Abrégé/Abstract:**

The invention relates to the field of organic chemistry, pharmacology and medicine and concerns a method for producing a copolymer of sodium carboxymethyl cellulose and gossypol having the formula (I), as well as the use thereof in a combined treatment for patients with autistic spectrum disorders and cognitive impairment.



(12) МЕЖДУНАРОДНАЯ ЗАЯВКА, ОПУБЛИКОВАННАЯ В СООТВЕТСТВИИ С
ДОГОВОРом О ПАТЕНТНОЙ КООПЕРАЦИИ (РСТ)(19) Всемирная Организация
Интеллектуальной Собственности
Международное бюро

(10) Номер международной публикации

WO 2012/050483 A1(43) Дата международной публикации
19 апреля 2012 (19.04.2012)**РСТ**(51) Международная патентная классификация:
C08B 15/00 (2006.01) *A61K 31/717* (2006.01)
A61P 25/28 (2006.01)

(21) Номер международной заявки: РСТ/RU2011/000785

(22) Дата международной подачи:
06 октября 2011 (06.10.2011)

(25) Язык подачи: Русский

(26) Язык публикации: Русский

(30) Данные о приоритете:
2010141697 11 октября 2010 (11.10.2010) RU(71) Заявитель (для всех указанных государств, кроме
US): **ОБЩЕСТВО С ОГРАНИЧЕННОЙ
ОТВЕТСТВЕННОСТЬЮ "НИАРМЕДИК ПЛЮС"**
(OBSHESTVO S OGRANICHENNOI OTVET-
STVENNOSTYU "NIARMEDIK PLUS") [RU/RU];
ул. 4-я Тверская-Ямская, 2/11 - 2 Москва., 125047,
Moscow (RU).


(72) Изобретатели; и

(75) Изобретатели/Заявители (только для US): **ЕРШОВ,
Феликс Иванович (ERSHOV, Felix Ivanovich)**
[RU/RU]; ул. Большая Полянка, 30 - 313 Москва.,
190098, Moscow (RU). **НЕСТЕРЕНКО, Владимир
Георгиевич (NESTERENKO, Vladimir Georgievich)**
[RU/RU]; Камергерский пер., 2 - 35 Москва., 103009,
Moscow (RU). **САРЫМСАКОВ, Абдушуккур
Абдухалилович (SARYMSAKOV, Abdushukur Ab-
dukhalilovich)** [UZ/UZ]; Массив Сергели-4, 21 - 19
Ташкент., 700209, Tashkent (UZ). **АЛЕКСЕЕВА,
Наталья Юрьевна (ALEKSEEVA, Natalya Uryevna)**
[RU/RU]; ул. Паршина, 37 - 101 Москва., 123103,
Moscow (RU).(74) Агент: **ОБЩЕСТВО С ОГРАНИЧЕННОЙ
ОТВЕТСТВЕННОСТЬЮ "ЮРИДИЧЕСКАЯ
ФИРМА ГОРОДИССКИЙ И ПАРТНЕРЫ" (LAW
FIRM "GORODISSKY & PARTNERS" LTD);** МИЦ,
Александр Владимирович ул. Б.Спасская, 25, стр. 3
Москва., 129090, Moscow (RU).(81) Указанные государства (если не указано иначе, для
каждого вида национальной охраны): AE, AG, AL,
AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM,
GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.(84) Указанные государства (если не указано иначе, для
каждого вида региональной охраны): ARIPO (BW,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ,
TZ, UG, ZM, ZW), евразийский (AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM), европейский патент (AL, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL,
PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Опубликована:

- с отчётом о международном поиске (статья 21.3)
- до истечения срока для изменения формулы изобретения и с повторной публикацией в случае получения изменений (правило 48.2(h))

(54) Title: METHOD FOR PRODUCING AND USING A COPOLYMER OF SODIUM CARBOXYMETHYL CELLULOSE AND GOSSYPOL

(54) Название изобретения : СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ СОПОЛИМЕРА
НАТРИЙКАРБОКСИМЕТИЛЦЕЛЛЮЛОЗЫ И ГОССИПОЛА

(57) Abstract: The invention relates to the field of organic chemistry, pharmacology and medicine and concerns a method for producing a copolymer of sodium carboxymethyl cellulose and gossypol having the formula (I), as well as the use thereof in a combined treatment for patients with autistic spectrum disorders and cognitive impairment.

(57) Реферат: Изобретение относится к области органической химии, фармакологии и медицины и касается способа получения сополимера натрийкарбоксиметилцеллюлозы и госсипола формулы (I) и его применения в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями.

METHOD FOR PRODUCING AND USING A COPOLYMER OF SODIUM
CARBOXYMETHYL CELLULOSE AND GOSSYPOL

The invention relates to the field of organic chemistry, pharmacology and medicine and concerns a method for producing a copolymer of sodium carboxymethyl cellulose and gossypol, its use in complex therapy of patients with autistic spectrum disorders and cognitive impairments, as well as a pharmaceutical composition comprising thereof to be used in the treatment of patients with autistic spectrum disorders and cognitive impairments, a combination for the treatment of patients with autistic spectrum disorders and cognitive impairments and a method for treating such patients.

Background

In recent decades, the aim of finding new agents for the treatment of autistic spectrum disorders accompanied by severe cognitive impairments becomes more medically and socially important in view of the duration of treatment, severe disability and maladjustment of patients with autistic spectrum disorders (V.M. Bashina, Childhood Autism, Moscow, "Meditsina", 1999).

Childhood autism is characterized by disorders of psychological development, autistic form of contact with others, disorders of speech and motor skills, activities and stereotyped behavior that lead to social maladjustment. A generally accepted concept of the etiology of autistic disorders does not currently

exist. The reasons are different - from endogenous genetic to exogenous organic and psychogenic. Childhood autism is considered to have a neurobiological basis and to be a result of general brain disorders.

There are known medicaments for the treatment of autistic spectrum disorders accompanied by severe cognitive impairments, which include, first of all, neuroleptics. Among neuroleptics for the treatment of autistic disorders with severe cognitive impairments there are useful aminazine, neuleptil, haloperidol, teraligen, triptazine, eglonil, azaleptin, chlorprothixene. In addition, such conditions are treated with antidepressants (anafranil, azaphene, pirazidole, amitriptyline, etc.), anticonvulsants (finlepsin, trileptal, topamax). (V.V. Kovalev, Psychiatry of childhood, Moscow, "Meditsin", 1979; V.M. Bashina, Childhood autism, Moscow, "Medicine", 1999).

It should be noted that the use of neuroleptics is accompanied by a high risk of undesirable side effects including extrapyramidal disorders, neuroleptic malignant syndrome, etc. A long-term treatment with such neuroleptics and other psychotropic agents results in evident side effects; they can cause psychological, neurological, and somato-vegetative disorders, which certainly limits the duration required for the neuroleptic therapy to be effective.

Sometimes, nootropics are used for the treatment of autistic disorders with severe cognitive impairments, as additional medicaments. Nootropics are considered to have a direct

activating effect on learning, improving memory and mental activity, i.e. cognitive function. The most commonly used nootropics in the treatment of autistic disorders with severe cognitive impairments are glycine, nootropil (Piracetam), encephabol (Pyriditol), aminorone (Gammalon), tanakan (L.M. Kuzenkova, O.I. Maslova, L.S. Namazova, etc., Nootropics in cognitive neuroscience in childhood // Manual for physicians, M., 2008, p.54). Dose regimen of nootropics is adjusted individually. Although nootropics are basically characterized by good tolerability in children with severe intellectual maldevelopment, their administration can lead to increased motor disinhibition, irritability, hyperthymia, and sleep impairment. Nootropics are described to have other side effects: Piracetam can cause dyspeptic disorders and increased coronary insufficiency; aminorone can cause dyspeptic disorders, fever-sensation and changes in blood pressure; Pyriditol can cause nausea and headache, and in children - psychomotor agitation. With that, Piracetam is contraindicated in renal failure; Pyriditol is contraindicated in high convulsion-readiness (L.M. Kuzenkova, O.I. Maslova, L.S. Namazova et al., Nootropics in cognitive neuroscience in childhood // Manual for physicians, M., 2008, p.54; S.Yu. Shtrygol, T.V. Kortunova, D.V. Shtrygol, Side Effects of Nootropics, Provisor, 2003, Issue 11).


In addition, in recent years a complex therapy with the above indicated drugs is most effective for the treatment of autistic disorders with severe cognitive impairments. However,

in this case, patients with very severe forms of autism often demonstrate resistance to neuroleptics, which requires increasing the average daily doses of medicaments. In this case, a desired effect is not always observed, and side effects are often increased.

In this context, the search for new additional agents for pathogenic therapy allowing for enhanced safety and efficacy of the treatment of mental illness is an important clinical and social challenge.

Summary of the Invention

The present inventors have surprisingly found that a known sodium salt of copolymer of carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1):




where

$$a:b:c = 1:(3-6):(5-7),$$

$$n = 40-50;$$

with a molecular weight of 120,000-130,000, and

of the following empirical formula:



wherein the sodium salt has antiviral activity and is used for the treatment of various viral infections, can be successfully used to treat patients with autistic spectrum disorders and cognitive impairments.

The compound and the method for producing thereof are described in RU 2270708. According to the known method an aqueous solution of sodium carboxymethyl cellulose is reacted with an aqueous solution of periodic acid or sodium periodate in the presence of isopropyl alcohol, followed by washing the resulting dialdehyde carboxymethyl cellulose with a mixture of isopropyl alcohol and water acidified with hydrochloric acid, treating with gossypol or gossypol-acetic acid and then with an aqueous solution of sodium hydroxide, and isolating the desired product by precipitation of a solvent.

The product obtained by the known method is contaminated with hydrochloric acid and isopropyl alcohol. In addition, operations involving hydrochloric acid solutions are always associated with certain difficulties.

Therefore, the object of the present invention is to develop an improved method for producing a copolymer of carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1) without the above indicated drawbacks.

Thus, an aspect of the present invention is a method for producing a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of the above formula (I), with a molecular weight of 120,000 to

130,000, wherein the method comprises reacting an aqueous solution of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 with an aqueous solution of periodic acid or sodium periodate when carbon dioxide is passed through the reaction solution until reaching a pH of 3.0 to 4.5, followed by isolation of dialdehyde carboxymethyl cellulose, treatment of the obtained product with gossypol or gossypol-acetic acid and then with an aqueous alkaline solution, and isolation of the desired product by precipitation with an organic solvent.

In order to isolate dialdehyde carboxymethyl cellulose, the reaction mixture, after reaching a pH of 3.0 to 4.5, is incubated at 5-8°C in a light-protected place for from 15 to 18 hours; the obtained dialdehyde carboxymethyl cellulose is precipitated with acetone and washed with an organic solvent, preferably with 70% aqueous acetone and 80% aqueous alcohol. Further treatment with gossypol or gossypol-acetic acid is performed at a temperature of 18 to 20°C, followed by neutralization of the reaction mixture with an alkaline solution and isolation of the desired product by precipitation with an organic solvent, preferably with acetone.

The proposed method excludes processes involving isopropyl alcohol and hydrochloric acid solutions, and provides a high yield of the desired product.

Another aspect of the present invention is a use of a copolymer of sodium carboxymethyl cellulose with a degree of

substitution of 0.35 to 0.80 and gossypol, of the above formula (I) in complex therapy of patients with autistic spectrum disorders and cognitive impairments. In particular, said polymer is used in combination with a medicament used for the treatment of cognitive disorders, which are selected from one or more neuroleptics, antidepressants, anticonvulsants, or a combination thereof. It is most preferable to use said polymer produced by the method according to the present invention.

Another aspect of the present invention is a pharmaceutical composition for the treatment of patients with autistic spectrum disorders and cognitive impairments, comprising, as an active agent, a therapeutically effective amount of a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of the above formula (I), and pharmaceutically acceptable additives.

The proposed pharmaceutical composition can be prepared in various formulations depending on the method of using thereof. An oral pharmaceutical composition can be used in the form of tablets, capsules or suspensions. In addition, suppositories can be used for rectal administration. The amount of an active agent in a pharmaceutical composition can vary within a wide range depending on various factors well known in the pharmaceutical field. As pharmaceutically acceptable additives, substances generally used for the above formulations can be used. For example, starch, such as potato starch, calcium or magnesium

stearate, lactose, and other pharmaceutically acceptable additives can be used as an excipient in tablets.

Currently, the problem of reducing the amount of allergenic agents in pharmaceutical preparations acquires more importance. In this regard, the use of ludipress comprising direct-compression lactose, povidone, pyrrolidone and crospovidone as a pharmaceutically acceptable additive allows complete replacement of lactose in pharmaceutical preparations and reduction of the amount of such allergenic agents such as starch, and reduction of the amount of calcium or magnesium stearate, increasing thereby the strength of tablets.

In this regard, in a preferred embodiment the proposed pharmaceutical composition can have the following ratio of the components, in wt.%:

active agent of the above formula (I) - 10.0-16.0

starch - 10.0-20.0

calcium or magnesium stearate - 0.6-0.8

ludipress - up to 100.

The pharmaceutical composition of the present invention is generally used in combination with a medicament used for the treatment of cognitive disorders, which is selected from one or more neuroleptics, antidepressants, anticonvulsants, or a combination thereof.

Thus, another aspect of the present invention is a combination for the treatment of patients with autistic spectrum disorders and cognitive impairments, comprising a

therapeutically effective amount of a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of the above formula (I) or a pharmaceutical composition comprising thereof; and a therapeutically effective amount of a medicament used for the treatment of cognitive disorders, which is selected from one or more neuroleptics, antidepressants, anticonvulsants or a combination thereof.

Accordingly, another aspect of the present invention is a method of treating patients with autistic spectrum disorders and cognitive impairments, comprising administering to a patient a therapeutically effective amount of a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of the above formula (I) in combination with a therapeutically effective amount of a medicament used for the treatment of cognitive disorders, which is selected from one or more neuroleptics, antidepressants, anticonvulsants, or a combination thereof.

The method can be used for the treatment of autistic disorders and cognitive impairments in 6-year children. A treatment regimen is selected by a specialist depending on the severity of a disease, condition and age of a patient. In particular, the treatment can be performed according to the following regimen: administration of a medicament 3 times per day for 5 days followed by the 5-day break. This ten-day cycle is repeated 2 times. The total duration of the treatment is 30

days. A dose of the active agent is 36 mg/day. Then, the course should be repeated.

A medicament used for the treatment of cognitive disorders is selected from neuroleptics, antidepressants and anticonvulsants. Aminazine, neuleptil, haloperidol, teraligen, triphthazine, eglonil, azaleptin, and chlorprothixene are used as commonly used neuroleptics. Medicaments such as anafranil, azaphene, pirazidole, and amitriptyline can be used as antidepressants. Finlepsin, trileptal, and topamax are commonly used as anticonvulsants.

Examples of producing a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I) and examples of pharmaceutical compositions comprising the copolymer and a method of treating are provided below.

Example of production 1-8

Procedure: A 3% aqueous solution is prepared from 100 g of sodium carboxymethyl cellulose (Na-CMC) with a degree of substitution of 0.35 in a reactor equipped with a mechanical stirrer. A 1% aqueous solution of periodic acid or sodium periodate in an amount of 1600 ml was added to the obtained Na-CMC solution. After complete mixing, gaseous carbon dioxide is passed through the solution until reaching a pH value of the solution of 3.0 to 4.5. Then, the reaction mixture is incubated at a temperature of 5 to 8°C for 15-18 hours. The reaction product is precipitated and washed with 70% acetone and 80%

aqueous alcohol solution from the excess of the oxidant and the products of degradation thereof. Gossypol (or gossypol-acetic acid) in an amount of 15% of the initial mass of sodium carboxymethyl cellulose is added to the washed product, which is dialdehyde carboxymethyl cellulose, and stirred at 18-20°C for 5 minutes. The reaction mixture is neutralized with a 6% aqueous solution of sodium hydroxide to a pH factor of 9.0. The desired product is isolated by precipitation with acetone followed by washing with the same solvent to complete removal of the excess of gossypol or its adduct, and drying on air. The yield of the desired product is 88%.

Specific data of examples 1-8 of the production of the claimed compound are shown in Table 1.

Table 1. Examples of the production of the claimed compound

Examples of the method embodiments	Degree of substitution of initial Na CMC	Concentration of aqueous Na CMC, %	Concentration of periodic acid or a salt thereof, %	Volume of a solution of periodic acid or a salt thereof, %	pH of the solution in oxidation of Na CMC	Temperature of incubation, °C	Time of incubation of the solution during oxidation, hours	Amount of gossypol or its adduct taken for a reaction, %	Temperature in mixing gossypol or its adduct, °C	Time of mixing dialdehyde, sec	pH of reaction mass in mixing in an alkaline solution	Characteristic viscosity, g	Molecular weight of the product	Water solubility, %	Yield of the desired product, %
1	0.35	3	1	1600	3.0	5	18	15.0	20	5.0	10.5	0.21	36300	99.0	95
2	0.50	5	2	700	3.5	7	16	10.0	22	4.0	10.0	0.19	30000	99.3	94
3	0.65	7	4	300	4.0	8	15	7.5	23	3.0	10.0	0.18	29100	99.6	93
4	0.80	10	6	170	4.5	5	15	5.0	25	3.0	10.5	0.12	24300	99.8	92
5	0.35	5	2	700	3.5	8	18	10.0	22	4.0	10.0	0.20	35400	99.1	94
6	0.50	3	1	1600	3.0	6	16	15.0	20	5.0	10.5	0.19	31300	99.4	93
7	0.65	10	6	170	4.5	7	16	5.0	25	3.0	10.5	0.17	30800	99.5	91
8	0.80	7	4	300	4.0	5	15	7.5	23	3.0	10.0	0.13	25100	99.7	92

Example of formulation 1. Tablets

Tablets were produced by a conventional method, in particular, by mixing components and pressing on a tableting machine. Examples of the quantitative composition of a tablet are shown in Table 2.

Table 2

Examples of the quantitative composition of a tablet

No of example	1		2		3	
Tablet weight	100 mg		150 mg		200 mg	
Components	Amount, mg	%	Amount, mg	%	Amount, mg	%
Active agent ^(*)	12	12	18	12	24	12
Potato starch	10	10	15	10	20	10
Calcium stearate	0.65	0.65	0.98	0.65	1.30	0.65
Ludipress	77.35	77.35	116.02	77.35	154.70	77.35

(*) - copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I).

The solubility test has demonstrated that 100% of the active agent transfers to the solution when dissolving a tablet in 500 ml of water on a mixer at 100 rpm for 45 minutes.

Treatment of 6-year children with autistic spectrum disorders and severe cognitive impairments

The efficacy and safety of the use of sodium carboxymethyl cellulose polymer with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I) in a complex therapy of 6-year children with autistic spectrum disorders and severe cognitive impairments were studied. The children were administered with a

medicament comprising a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I) (tablets containing 12 mg of the active agent, which composition is shown in Table 2) on the background of basic therapy with neuroleptics such as neuleptil, haloperidol, aminazine, teraligen, triptazine, eglonil, azaleptin chlorprothixene. Antidepressants (e.g., anafranil) and anticonvulsants (finlepsin, trileptal, or topamax) were used in some cases. Neuroleptics, antidepressants and anticonvulsants were used in optimal therapeutic doses. The group of patients administered, additionally to the basic therapy, with a medicament comprising a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I) demonstrated a decreased resistance to therapy with neuroleptics, especially the patients with very severe autism. Before the administration of a medicament comprising a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I), these patients did not demonstrate a positive therapeutic effect in increasing doses of neuroleptics, and in some cases, complications of the conducted therapy were amplified to the loss of neatness skills (encopresis, enuresis). When the therapy was supplemented with a medicament comprising a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I), the manifestations of encopresis and enuresis ceased, catatonic disorders decreased, cognitive functions improved, and speech appeared. In patients


with mild to moderate autism, restricted repetitive behavior disappeared.

The mental condition of the patients is improved when administering a medicament comprising a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I). The use of sodium carboxymethyl cellulose polymer with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I) as a component of complex therapy of children with autistic spectrum disorders and severe cognitive impairments allows elimination of the body's resistance to psychotropic drugs, thereby achieving a therapeutic effect with decreased single and daily doses of the medicaments for basic therapy, and a significant improvement in cognitive functions of patients. The use of a medicament comprising a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I) does not have negative side effects on a patient. The medicament is well tolerable; toxic and allergic reactions were not reported.

Thus, the present invention allows the production of a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (I) by a safe work method providing a high yield of the desirable product and allows an effective use of said product in complex therapy of patients with autistic spectrum disorders and cognitive impairments.

CLAIMS

1. A method of producing a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1):



where

$a:b:c = 1:(3-6):(5-7)$,


$n = 40-50$;

with a molecular weight of 120,000-130,000,

the method comprising reacting an aqueous solution of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 with an aqueous solution of periodic acid or sodium periodate, followed by isolation of dialdehyde carboxymethyl cellulose, treatment of the resulting product with gossypol or gossypol-acetic acid and then with an aqueous alkaline solution, and isolation of a desired product by precipitation with an organic solvent, **characterized in that** the aqueous solution of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 is reacted with the aqueous solution of periodic

acid or sodium periodate when passing carbon dioxide through the reaction solution until reaching a pH of 3.0 to 4.5.

2. The use of a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1):



where

$a:b:c = 1:(3-6):(5-7)$,

$n = 40-50$;

with a molecular weight of 120,000-130,000,


in complex therapy of patients with autistic disorders and cognitive impairments.

3. The use according to claim 2, wherein the copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1), is produced by the method according to claim 1.

4. The use according to claim 2 or 3, wherein the copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1) is used in combination with a medicament for treatment of cognitive

disorders selected from one to more neuroleptics, antidepressants, anticonvulsants or a combination thereof.

5. A pharmaceutical composition for use in complex therapy of patients with autistic disorders and cognitive impairments, comprising, as an active agent, a therapeutically effective amount of a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1)



where

$a:b:c = 1:(3-6):(5-7)$,

$n = 40-50$;

with a molecular weight of 120,000-130,000,

and pharmaceutically acceptable additives.

6. The pharmaceutical composition according to claim 5, comprising following components, % by weight:

the active agent of formula (1) - 10.0-16.0,


starch - 10.0-20.0,

calcium or magnesium stearate - 0.6-0.8

ludipress - up to 100.

7. The pharmaceutical composition according to claim 5 or 6, for use in a combination with a medicament for treatment of cognitive disorders, selected from one or more neuroleptics, antidepressants, anticonvulsants or a combination thereof.

8. A combination for treatment of patients with acoustic disorders and cognitive impairments, comprising a therapeutically effective amount of a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1)



where

$a:b:c = 1:(3-6):(5-7)$,

$n = 40-50$;


with a molecular weight of 120,000-130,000,

or the pharmaceutical composition according to claim 5 or 6;

and

a therapeutically effective amount of a medicament for treatment of cognitive disorders, selected from one or more neuroleptics, antidepressants, anticonvulsants or a combination thereof.

9. A method for treating patients with autistic disorders and cognitive impairments, comprising administering to a patient a therapeutically effective amount of a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1)



where


$a:b:c = 1:(3-6):(5-7)$,

$n = 40-50$;

with a molecular weight of 120,000-130,000,

or the pharmaceutical composition according to claim 5 or 6, in combination with a therapeutically effective amount of a medicament for treatment of cognitive disorders, selected from one or more neuroleptics, antidepressants, anticonvulsants or a combination thereof.

10. A use of a copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1)



where


$a:b:c = 1:(3-6):(5-7)$,

$n = 40-50$;

with a molecular weight of 120,000-130,000,

for producing the pharmaceutical composition according to claim 5 or 6.

11. The use according to claim 10, wherein the copolymer of sodium carboxymethyl cellulose with a degree of substitution of 0.35 to 0.80 and gossypol, of formula (1) is produced by the method of claim 1.



(I)